Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

NOVO NORDISK PHARMACEUTICALS A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.4% 0.4%   Bankruptcy risk   1.8% 0.9% 0.9% 0.6% 1.5% 2.6% 3.6% 3.6%   Credit score (0-100)   74 89 90 97 75 61 52 52   Credit rating   A A A AA A BBB BBB BBB   Credit limit (kDKK)   7.8 1,065.7 217,310.1 278,448.2 375.8 0.4 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 3,941 0 0 0 0 0   Gross profit   0.0 0.0 3,941 24,614 6,218 -46.0 0.0 0.0   EBITDA   -33.0 -39.0 3,903 49,228 12,436 -92.0 0.0 0.0   EBIT   -33.0 -39.0 3,903 52,027 9,772 -5,904 0.0 0.0   Pre-tax profit (PTP)   -1,991.0 3,721.0 -2,283.0 1,034.0 -6,157.0 -1,189.0 0.0 0.0   Net earnings   -1,984.0 3,722.0 -2,368.0 1,330.0 -5,443.0 -2,258.0 0.0 0.0   Pre-tax profit without non-rec. items   -1,991 3,721 -2,283 25,648 61.0 -1,235 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   11,847 15,569 2,849,704 2,851,034 105,591 103,333 2,331 2,331   Interest-bearing liabilities   0.0 0.0 19,974 21,071 42,552 6,773 3,669 3,669   Balance sheet total (assets)   11,880 15,602 2,958,624 3,048,757 210,245 111,169 6,000 6,000   Net Debt   0.0 -1,048 18,867 19,590 37,300 -98,359 3,669 3,669     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 3,941 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 0.0 3,941 24,614 6,218 -46.0 0.0 0.0   Gross profit growth   0.0% 0.0% 0.0% 524.6% -74.7% 0.0% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   11,880 15,602 2,958,624 3,048,757 210,245 111,169 6,000 6,000   Balance sheet change%   -14.3% 31.3% 18,863.1% 3.0% -93.1% -47.1% -94.6% 0.0%   Added value   -33.0 -39.0 3,903.0 52,027.0 9,772.0 -5,904.0 0.0 0.0   Added value %   0.0% 0.0% 99.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 11,831 -5,831 0 0   Net sales trend   0.0 0.0 0.0 -1.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 1.0 2.0 3.0 -1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 99.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 99.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 0.0% 99.0% 211.4% 157.2% 12,834.8% 0.0% 0.0%   Net Earnings %   0.0% 0.0% -60.1% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% -60.1% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% -57.9% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -0.3% 27.1% 0.1% 1.7% 0.6% -0.8% 0.0% 0.0%   ROI %   -0.3% 27.2% 0.1% 1.8% 0.6% -1.0% 0.0% 0.0%   ROE %   -15.5% 27.2% -0.2% 0.0% -0.4% -2.2% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   99.7% 99.8% 93.5% 93.5% 50.2% 93.0% 38.9% 38.9%   Relative indebtedness %   0.0% 0.0% 2,763.8% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 2,735.7% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.0% 2,687.2% 483.4% 39.8% 299.9% 106,912.0% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.7% 0.7% 40.3% 6.6% 157.4% 157.4%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 39.5% 128.5% 30.6% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   25.2 32.0 4.7 9.0 1.9 13.4 0.0 0.0   Current Ratio   25.2 32.0 4.7 9.0 1.9 13.4 0.0 0.0   Cash and cash equivalent   0.0 1,048.0 1,107.0 1,481.0 5,252.0 105,132.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 2,383.1% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   797.0 1,024.0 73,913.0 183,088.0 93,760.0 97,333.0 -1,834.5 -1,834.5   Net working capital %   0.0% 0.0% 1,875.5% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0